Novo Nordisk to Appeal Court Decision on IRA Price-Setting Rules

Drug manufacturers have seen their arguments challenging the validity of the price-setting provisions of the Inflation Reduction Act (IRA) consistently dismissed in court. A move for summary judgement made by Novo Nordisk, one of the pharmaceutical companies impacted by the first round of price talks, has been turned down. The corporation expressed worries about the separation of powers between government branches and questioned the "voluntary" nature of the price policy, claiming that it infringes its right to free expression. A prior decision on Johnson & Johnson and Bristol Myers Squibb's combined motion against the IRA was rendered by District Judge Zahid Quraishi, emphasising the option that businesses have when selling medications through Medicare.

The court denied Novo's request for summary judgement, maintaining his earlier conclusions that the IRA complies with the company's constitutional demands and that involvement in the discussions is voluntary. Nonetheless, the government's request for summary judgement was granted by the judge. A representative for Novo expressed unhappiness with the ruling and said the company will file an appeal right away.

The pharmaceutical industry's losing war against the IRA is just getting started. Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb's, and other recent instances are listed below. A Texas judge dismissed a related claim filed by the lobbying organisation PhRMA. All pharmaceutical companies whose products were impacted by the discussions consented to take part in the process in October, notwithstanding their objections.